Neuroprotection in Stroke

Submission deadline: 31 July 2023
Special Issue Editor
  • Zdravka Poljakovic, MD, PhD
    Department of Neurology, University Hospital Centre Zagreb, Kispaticeva 12, Zagreb, Croatia
    Interests: Thrombus Aspiration; Brain Ischemia; Solitaire; Idarucizumab; Dabigatran Etexilate; Anticoagulant Agent; Atrial Fibrillation; Anticoagulant Agent; Hemorrhage
Special Issue Information

Dear Colleagues,

Despite the development of advanced neuroimaging and neuro-interventional techniques, stroke remains a devastating disease with an uncertain final outcome. Mortality rates from stroke are falling worldwide, but this disease is still the leading cause of invalidity. Modern recanalization techniques have made great progress towards the causal treatment of stroke. Unfortunately, however, at least a third of treated patients do not undergo reperfusion despite sufficient recanalization of the occluded blood vessel. New insights into stroke pathology indicate there is progressive neuronal loss and the development of secondary neurodegeneration following acute vascular injury. Published data also suggests that progressive neuronal loss and neurodegeneration after a stroke alters the levels of amyloid beta and leads to cognitive decline, thus showing similarities with so called “neurodegeneration”. However, pure recanalization is often insufficient to achieve reperfusion, and therefore futile recanalization and reperfusion injury remain important clinical problems. Neuroprotection offers some hope in this regard and may address several unanswered questions in vascular brain pathology. Unfortunately, despite some experimental success with neuroprotection, there is still a lack of evidence for clinical efficacy. The aim of this special issue is to highlight ongoing trials and research in neuroprotection, as well as to provide a critical overview of the neuroprotective drugs used in both experimental and clinical settings. This will include a discussion of various neuroprotective agents and the possible use of neuroprotection strategies for all types of stroke.

Dr. Zdravka Poljakovic

Guest Editor

Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2200 USD. Submitted manuscripts should be well formatted in good English.

Published Paper (2 Papers)
Back to top